iSBTc 23rd Annual Meeting

October 31 - November 2, 2008
Westin Gaslamp Quarter Hotel
San Diego, CA

Presentation Slides & Schedule
Slides for select presentations below have been provided by the corresponding speaker for your convenience.
Please click the next to the speaker's name to log in to view the presentations.

Wednesday, October 29
11:00 am - 7:00 pm Registration Open
Thursday, October 30
6:30 am - 6:00 pm Registration Open
Friday, October 31
6:30 am - 5:00 pm Registration Open
10:00 am - 4:00 pm Exhibit Hall Open
10:00 am - 7:30 pm Poster Hall Open
7:50 am - 8:00 am President's Welcome
Jon M. Wigginton, MD - Merck & Co., Inc.
8:00 am - 8:45 am Richard V. Smalley, MD Memorial Lectureship
Different Tumor Antigens in the Immunotherapy of Cancer: Are we Selecting the Right Target?
 Giorgio Parmiani, MD - San Raffaele Foundation
8:45 am - 11:30 am Plenary Session: Enhancing Cancer Vaccines
Co-Chairs: Glenn Dranoff, MD - Dana-Farber Cancer Institute
W. Martin Kast, PhD - University of Southern California
8:45 am - 9:15 am Enhancing Cancer Vaccines Through Heterologous Prime Boost Strategies that Include VRP and that Induce Lifelong Protection from Prostate Cancer and Therapy of Cervical Cancer in Mice and Robust Cell-Mediated Immunity in Rhesus Macaques
 W. Martin Kast, PhD - University of Southern California
9:15 am - 9:30 am Interleukin-15 and its Receptor Enhance Antitumor Activity Following a Genetically-Modified Dendritic Cell Vaccine
Jason C. Steel, PhD - National Cancer Institute, Metabolism Branch, NIH
9:30 am - 9:45 am T Cell Receptor-Dependent and Independent Pathways Control PD-1 Expression on CD8+ T cells Generated upon Intra Lymph Node Immunization
 Adrian Bot, MD, PhD - MannKind Corporation
9:45 am - 10:00 am Cellular Immunotherapy and Immune Regulation in Ovarian Cancer
 Martin J. Cannon, PhD - University of Arkansas for Medical Sciences
10:00 am - 10:15 am Intra-Lymphatic Continuous Infusion of Dendritic Cells in Patients with Advanced Melanoma: Early Indication of Clinical Efficacy
Pawel Kalinski, MD, PhD - University of Pittsburgh Cancer Institute
10:45 am - 11:00 am Clinical Response to the MAGE-A3 Immunotherapeutic in Metastatic Melanoma Patients is Associated with a Specific Gene Expression Profile Present at the Tumor Site
Jamila Louahed, PhD - GlaxoSmithKline Biologicals SA
11:00 am - 11:30 am Balancing Tumor Immunity and Inflammation
Glenn Dranoff, MD - Dana-Farber Cancer Institute
11:30 am - 1:00 pm Lunch with Poster Viewing
1:00 pm - 3:00 pm Plenary Session: Adoptive Transfer
Co-Chairs: Helen E. Heslop, MD - Baylor College of Medicine
William J. Murphy, PhD - University of Nevada, School of Medicine
1:00 pm - 1:30 pm Three Ways to Enhance the Destructive Power of Tumor-Specific T Cells
 Nicholas P. Restifo, MD - National Cancer Institute
1:30 pm - 2:00 pm Engineering GVL by T-Cell Genetic Modification
 Michael C.V. Jensen, MD - City of Hope / Beckman Research Institute
2:00 pm - 2:15 pm Targeted Elimination of Brain Tumor Stem Cells with T Cell Therapies
Christine Brown, PhD - City of Hope National Medical Center
2:15 pm - 2:30 pm Intralesional Placement of Lymphokine-Activated Killer Cells After Resection of Primary Glioblastoma
Robert O. Dillman, MD, FACP - Hoag Cancer Center
2:30 pm - 2:45 pm Provision of CD4+ T Cell Help Prevents Tolerization of Tumor-Specific CTLs and Enhances Tumor Immunity in a Murine Model of Prostate Cancer
Kimberly A. Shafer-Weaver, PhD - SAIC/NCI-Frederick
2:45 pm - 3:00 pm Rapid Expansion of Melanoma TIL in Adoptive Cell Therapy Leads to Loss of CD28 and Reduced Proliferative Potential in the MART-1-Specific T Cell Population
 Yufeng Li - MD Anderson Cancer Center
3:15 pm - 4:45 pm Concurrent Session I: TH-17, Cytokines and T Cell Subsets
Co-Chairs: Martin Oft, MD - Schering-Plough Biopharma (formerly DNAX)
Hideaki Tahara, MD, PhD - University of Tokyo
3:15 pm - 3:40 pm IL-23 Promotes Tumor Associated Inflammation and Subverts Immune Surveillance
 Martin Oft, MD - Schering-Plough Biopharma (formerly DNAX)
3:40 pm - 4:05 pm Potent Anti-Tumor Immunity and Both TH-1 and TH-17 Promotion Associated with IL-23 Administration
 Hideaki Tahara, MD, PhD - University of Tokyo
4:05 pm - 4:30 pm TH-17 Cells in Ovarian Cancer Patients
Ilona Kryczek, PhD - University of Michigan
4:30 pm - 4:45 pm CD40 Dependent Induction of TH-17 Effector Cells from T Regulatory Cells Using the Immune Modulator B7-DC XAb
Suresh Radhakrishnan, PhD - Mayo Clinic, College of Medicine
This abstract was fully retracted May 28, 2010 upon request of the Principal Investigator.
3:15 pm - 4:45 pm Concurrent Session II: Endpoints, Response Criteria for Clinical Trial Design
Co-Chairs: Thomas A. Davis, MD - AVANT Immunotherapeutics, Inc.
Jeffrey Schlom, PhD - National Cancer Institute, NIH
3:15 pm - 3:40 pm Immunotherapies in Combination with Other Therapeutic Modalties: New Paradigms for Clinical Trial Design
Jeffrey Schlom, PhD - National Cancer Institute, NIH
3:40 pm - 3:55 pm Overall Survival and New Patterns of Response in Patients with Advanced Melanoma Treated with Ipilimumab
 Steven J. O'Day, MD - The Angeles Clinic and Research Institute
3:55 pm - 4:15 pm Endpoints for Biologic Therapeutics in Oncology
 Peter Bross, MD - FDA - Office of Cellular, Tissue, and Gene Therapies
4:15 pm - 4:45 pm Panel Discussion
5:00 pm - 5:30 pm iSBTc Membership Business Meeting (iSBTc Members Only)
5:30 pm - 7:30 pm Reception with Poster Viewing
Saturday, November 1
7:00 am - 6:00 pm Registration Open
7:00 am - 8:00 am Continental Breakfast
8:00 am - 8:45 am Keynote Address
Cancer Immunoediting: Distinct Roles for Innate and Adaptive Immunity in Cancer Control and Promotion
 Robert D. Schreiber, PhD - Washington University in St. Louis
8:45 am - 11:30 am Plenary Session: Tumor Escape / Tumor Microenvironment
Co-Chairs: Thomas F. Gajewski, MD, PhD - University of Chicago
Weiping Zou, MD, PhD - University of Michigan
8:45 am - 9:15 am Innate Immune Signals that Mediate Host Awareness of Tumor and Promote Adaptive Immune Responses Against Tumor Antigens
 Thomas F. Gajewski, MD, PhD - University of Chicago
9:15 am - 9:30 am Persistent High Grade Cervical Dysplasia Excludes CD8+ T Cells
Cornelia Trimble, MD - Johns Hopkins University
9:30 am - 10:00 am Inhibitory B7 Family Members (B7-H1 and B7-H4) in the Tumor Microenvironment
 Weiping Zou, MD, PhD - University of Michigan
10:00 am - 10:15 am L-Arginine Availability Regulates Cyclin D3 mRNA Stability in Human T Cells by Controlling HuR Expression
Paulo C. Rodriguez, PhD - Louisiana State University Health Science Center
10:45 am - 11:15 am Correcting the Anergy of Human Tumor-Infiltrating Lymphocytes?
Pierre van der Bruggen, PhD - Ludwig Institute for Cancer Research
11:15 am - 11:30 am Evidence for Selection of a Resistant Tumor Microenvironment Following Successful Clinical Response to a Multi-Peptide + IL-12 Melanoma Vaccine
 Yuanyuan Zha, PhD - Human Immunologic Monitoring Facility, University of Chicago
11:30 am - 1:00 pm Lunch with Poster Viewing
1:00 pm - 2:20 pm iSBTc Presidential Abstract Session
Chair: Jon M. Wigginton, MD - Merck & Co., Inc.
1:00 pm - 1:20 pm Increasing Immunostimulatory Ability of Tolerogenic APCs Enhances Anti-Tumor Immunity
Stephanie K. Watkins, PhD - National Cancer Institute - Frederick, NIH
1:20 pm - 1:40 pm CCL28 a New Link Between Hypoxia Angiogenesis and Tumor Immune Evasion
 Andrea Facciabene, PhD - University of Pennsylvania
1:40 pm - 2:00 pm Cytotoxic T Lymphocyte-associated Antigen 4 Blockade Enhances Polyfunctional NY-ESO-1 Specific T Cell Responses in Metastatic Melanoma Patients with Tumor Regression
 Jianda Yuan, MD, PhD - Memorial Sloan-Kettering Cancer Center
2:00 pm - 2:20 pm Radiofrequency Ablation with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect Against Murine Colon Adenocarcinoma
 Erik Johnson, MD - University of Wisconsin-Madison
2:45 pm - 4:15 pm Concurrent Session I: Tumor Targeting Monoclonal Antibodies
Co-Chairs: Helen Chen, MD - National Cancer Institute, CTEP
Greg Lazar, PhD - Xencor, Inc.
2:45 pm - 3:15 pm Antibody and Small Moldular Immune Pharmaceutical Therapies for Patients with Chronic Lymphocytic Leukemia: A Major Step Forward
 John C. Byrd, MD - The Ohio State University
3:15 pm - 3:30 pm Phase I/II Study of CR011-vcMMAE, an Antibody-Drug Conjugate Targeting GPNMB, for the Treatment of Patients with Advanced Melanoma
 Patrick Hwu, MD - MD Anderson Cancer Center
3:30 pm - 4:00 pm Optimizing Engagement of the Immune System by Anti-Tumor Antibodies
 John R. Desjarlais, PhD - Xencor, Inc.
4:00 pm - 4:15 pm Cetuximab Mediated Antibody Dependent Cellular Cytotoxicity by NK Cells Expressing Polymorphic Fc Gamma Receptor (FcyR)IIIa
Robert L. Ferris, MD, PhD - University of Pittsburgh Cancer Institute
2:45 pm - 4:15 pm Concurrent Session II: Innate Immunity to Tumors
Co-Chairs David Raulet, PhD - University of California, Berkeley
Giorgio Trinchieri, MD - National Cancer Institute
2:45 pm - 3:15 pm Innate Resistance, Inflammation, and Cancer
Giorgio Trinchieri, MD - National Cancer Institute
3:15 pm - 3:45 pm Role of NKG2D in Tumor Surveillance
 David Raulet, PhD - University of California, Berkeley
3:45 pm - 4:00 pm Innate Immunity Can Contribute to the Shaping of Tumor Immunogenicity in the Absence of Adaptive Immunity
 Jack D. Bui, MD, PhD - University of California, San Diego
4:00 pm - 4:15 pm Spontaneous CTL-mediated Rejection of GP33-positive Lewis Lung Carcinoma is Dependent on an IFNAR Competent Environment
Ulrich Kalinke, PhD - TWINCORE, Centre for Experimental and Clinical Infection Research
4:30 pm - 5:00 pm Update: 2007 Workshop on Future Opportunities for Combination Biological
Therapy of Cancer
Speaker:  Jon M. Wigginton, MD - Merck & Co., Inc.
5:00 pm - 5:15 pm Award Presentations
5:15 pm - 7:00 pm Presidential Reception with Poster Viewing
Sunday, November 2
7:00 am - 11:00 am Registration Open
8:00 am - 10:15 am Plenary Session: Cancer Stem Cells and the Host Response
Co-Chairs: Madhav Dhodapkar, MD - The Rockefeller University
Max Wicha, MD - University of Michigan
8:00 am - 8:42 am Regulation of Breast Cancer Stem Cells by the Microenvironment
 Max Wicha, MD - University of Michigan
8:42 am - 9:24 am Harnessing the Immune System to Target Stem Cell Genes in Myeloma
Madhav Dhodapkar, MD - The Rockefeller University
9:24 am - 9:49 am Characterization of the Immune Profile of Cancer Stem Cells Isolated from Human Glioblastoma
 Cristina Maccalli, PhD - San Raffaele Foundation Scientific Institute
9:49 am - 10:15 am CD133 as a Potential Target of Anti-cancer Stem Cell Immunotherapy: Identification of a HLA-A*02 Restricted CD133 Epitope
John S. Yu, MD - Cedars Sinai Medical Center
10:15 am - 10:30 am Annual Meeting Adjourns
Sunday Hot Topic Symposium
10:30 am - 12:00 pm Hot Topic Session - "Anti-CTLA-4: Issues in Development and Regulatory Approval"
Program to include invited speakers, panel discussion/debate and audience questions.

Click here for more information, including a detailed schedule and faculty listing.

Creative Commons License
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.